GEN Exclusives

More »

The Lists

More »
Mar 3, 2014

The Top 25 Best-Selling Drugs of 2013

Find out how many billions these blockbusters raked in.

The Top 25 Best-Selling Drugs of 2013

These therapeutics didn’t bring in less than $3 billion last year. [© grandeduc - Fotolia.com]

  • #14. Neulasta (pegfilgrastim)

    Sponsor(s): Amgen2

    Indication(s): Neutropenia caused by cancer chemotherapy

    2013 sales: $4.392 billion

    2012 sales: $4.092 billion

    % Change: 7.3%

    Q4 2013 sales: $1.098 billion, up 10.5% from $994 million in Q4 2012

  • #13. Lyrica (pregabalin)

    Sponsor(s): Pfizer

    Indication(s): Fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, and pain after shingles

    2013 sales: $4.595 billion

    2012 sales: $4.158 billion

    % Change: 10.5%

    Q4 2013 sales: $1.260 billion, up 11.3% from $1.132 billion in Q4 2012

  • #12. Gleevec (also sold as Glivec, imatinib mesylate)

    Sponsor(s): Novartis

    Indication(s): Specified patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML); specified patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); adults with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; adults with aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknown; adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and all patients FIP1L1-PDGFRα fusion kinase negative or unknown; adults with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans; patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs); adults after surgery for removal of KIT (CD117)-positive GISTs

    2013 sales: $4.693 billion

    2012 sales: $4.675 billion

    % Change: 0.4%

    Q4 2013 sales: $1.227 billion, up 4.1% from $1.179 billion in Q4 2012

  • #11. Cymbalta (duloxetine)

    Sponsor(s): Eli Lilly and Shionogi

    Indication(s): Major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain, and fibromyalgia; management of chronic musculoskeletal pain due to chronic osteoarthritis pain and chronic low back pain

    2013 sales: $5.191 billion ($5.084 billion Lilly + $0.107 billion [¥10.9 billion] Shionogi)

    2012 sales: $5.082 billion ($4.994 billion Lilly + $0.088 billion [¥9.0 billion] Shionogi)

    % Change: 2.1%

    Q4 2013 sales: $0.863 billion ($0.883 billion Lilly + $0.030 billion [¥3.1 billion] Shionogi), down 40.2% from $1.443 billion ($1.420 billion Lilly + $0.023 billion [¥2.4 billion] Shionogi) in Q4 20123

  • #10. Abilify (aripiprazole)

    Sponsor(s): Otsuka Pharmaceutical and Bristol-Myers Squibb4

    Indication(s): Schizophrenia; bipolar I disorder, both alone and an adjunct to lithium or valproate; agitation associated with schizophrenia or bipolar I disorder; adjunctive treatment of major depressive disorder; irritability associated with autistic disorder

    2013 sales: $5.265 billion (¥537.9 billion)4

    2012 sales: $4.088 billion (¥417.7 billion)4

    % Change: 28.8%

    Q4 2013 sales: $1.450 billion (¥148.2 billion), up 42.0% from $1.022 billion (¥104.4 billion) in Q4 20124

  • #9. Crestor (rosuvastatin calcium)

    Sponsor(s): AstraZeneca and Shionogi

    Indication(s): Reduction of cholesterol and buildup of plaque in arteries

    2013 sales: $5.994 billion ($5.622 billion AstraZeneca + $0.372 billion [¥38.1 billion] Shionogi)

    2012 sales: $6.618 billion ($6.253 billion AstraZeneca + $0.365 billion [¥37.4 billion] Shionogi)

    % Change: -9.4%

    Q4 2013 sales: $1.566 billion [$1.463 billion AstraZeneca + $0.103 billion (¥10.6 billion) Shionogi], down 8.8% from $1.718 billion [$1.622 billion AstraZeneca + $0.096 billion (¥9.8 billion) (Shionogi)] in Q4 2012

  • #8. Herceptin (trastuzumab)

    Sponsor(s): Roche

    Indication(s): HER2 overexpressing breast cancer; HER2 overexpressing metastatic gastric or gastroesophageal junction cancer

    2013 sales: $6.839 billion (CHF 6.079 billion)

    2012 sales: $6.624 billion (CHF 5.889 billion)

    % Change: 3.1%

    Q4 2013 sales: $1.671 billion (CHF 1.485 billion), up 1.9% from $1.639 billion (CHF 1.457 billion) in Q4 2012

  • #7. Avastin (bevacizumab)

    Sponsor(s): Roche

    Indication(s): Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma, and metastatic kidney

    2013 sales: $7.037 billion (CHF 6.254 billion)

    2012 sales: $6.485 billion (CHF 5.764 billion)

    % Change: 8.5%

    Q4 2013 sales: $1.737 billion (CHF 1.544 billion), up 6.1% from $1.637 billion (CHF 1.455 billion) in Q4 2012

  • #6. Lantus (insulin glargine)

    Sponsor(s): Sanofi

    Indication(s): Once-daily treatment for diabetes

    2013 sales: $7.849 billion (€5.715 billion)

    2012 sales: $6.648 billion (€4.960 billion)

    % Change: 15.2%

    Q4 2013 sales: $2.077 billion (€1.512 billion), up 13.3% from $1.834 billion (€1.335 billion) in Q4 2012

  • #5. Enbrel (etanercept)

    Sponsor(s): Amgen and Pfizer

    Indication(s): Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis

    2013 sales: $8.325 billion ($4.551 billion Amgen + $3.774 billion Pfizer)5

    2012 sales: $7.963 billion ($4.236 billion Amgen + $3.737 billion Pfizer)5

    % Change: 4.5%

    Q4 2013 sales: $2.205 billion ($1.200 billion Amgen + $1.005 billion Pfizer), up 4.1% from $2.118 billion ($1.161 billion Amgen + $0.957 billion Pfizer) in Q4 2012

  • #4. Advair (fluticasone and salmeterol; sold in some countries as Seretide)

    Sponsor(s): GlaxoSmithKline

    Indication(s): Asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

    2013 sales: $8.783 billion (£5.274 billion)

    2012 sales: $8.402 billion (£5.046 billion)

    % Change: 4.5%

    Q4 2013 sales: $2.328 billion (£1.398 billion), up 6.8% from $2.180 billion (£1.309 billion) in Q4 2012

  • #3. Rituxan (rituximab, MabThera)

    Sponsor(s): Roche (Genentech) and Biogen Idec

    Indication(s): Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis

    2013 sales: $8.920 billion ($7.820 billion [CHF 6.951 billion] Roche + $1.1 billion Biogen Idec)6

    2012 sales: $8.646 billion ($7.546 billion [CHF 6.707 billion] Roche + $1.1 billion Biogen Idec)6

    % Change: 3.2%

    Q4 2013 sales: $2.232 billion ($1.963 billion [CHF 1.745 billion] Roche + $0.269 billion Biogen Idec), up 1.3% from $2.204 billion ($1.923 billion [CHF 1.709 billion] Roche + $0.281 billion Biogen Idec) in Q4 2012

  • #2. Remicade (infliximab)

    Sponsor(s): Johnson & Johnson and Merck & Co.

    Indication(s): Moderately to severely active rheumatoid arthritis in adults (with methotrexate); Crohn's disease in children six years and older, and in adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children six years and older, and in adults that have not responded well to other medicines

    2013 sales: $8.944 billion ($6.673 billion J&J + $2.271 billion Merck & Co.)

    2012 sales: $8.215 billion ($6.139 billion J&J + $2.076 billion Merck & Co.)

    % Change: 8.9%

    Q4 2013 sales: $2.332 billion, up 13.6% from $2.053 billion in Q4 2012 (2013: $1.712 billion J&J + $0.620 billion Merck & Co.; 2012: $1.504 billion J&J + $0.549 billion Merck & Co.)

  • #1. Humira (adalimumab)

    Sponsor(s): AbbVie7

    Indication(s): Moderate to severe rheumatoid arthritis; moderate to severe chronic plaque psoriasis; moderate to severe Crohn’s disease; moderate to severe ulcerative colitis; ankylosing spondylitis; psoriatic arthritis; moderate to severe polyarticular juvenile idiopathic arthritis

    2013 sales: $10.659 billion

    2012 sales: $9.265 billion

    % Change: 15.0%

    Q4 2013 sales: $3.039 billion, up 13.4% from $2.681 billion in Q4 2012



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?